Leukemia Clinical Trials in Caen
17 recruitingCaen, France
Showing 1–17 of 17 trials
Recruiting
Phase 2
A Study Evaluating the Efficacy and Safety of Pirtobrutinib in Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Loxo Oncology, Inc.249 enrolled133 locationsNCT06588478
Recruiting
Phase 3
Quizartinib or Placebo Plus Chemotherapy in Newly Diagnosed Patients With FLT3-ITD Negative AML
Leukemia
Daiichi Sankyo700 enrolled292 locationsNCT06578247
Recruiting
Phase 2
Study Comparing the Efficacy of 2 RIC Regimens (Clofarabine vs Fludarabine) in Adults With AML Eligible to Allo-SCT
Acute Myeloid Leukemia in Remission
Nantes University Hospital302 enrolled23 locationsNCT05917405
Recruiting
Phase 1Phase 2
AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia
B-cell Acute Lymphoblastic Leukemia (B-ALL)
AstraZeneca163 enrolled79 locationsNCT06137118
Recruiting
Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia (AML)
Acute Leukemia French Association5,000 enrolled30 locationsNCT04777916
Recruiting
Not Applicable
MoleculAr Profiling for Pediatric and Young Adult Cancer Treatment Stratification 2
Solid TumorLeukemia
Gustave Roussy, Cancer Campus, Grand Paris1,800 enrolled29 locationsNCT05691608
Recruiting
Phase 3
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Leukemia, Acute Lymphoblastic
Mats Heyman6,430 enrolled130 locationsNCT04307576
Recruiting
Phase 3
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Acute Myeloid Leukemia
Stichting Hemato-Oncologie voor Volwassenen Nederland227 enrolled119 locationsNCT07075016
Recruiting
Relation Between Venetoclax Plasma Concentration and Remission in Adults with Acute Myeloid Leukemia (PREDICLAX)
Adult Acute Myeloid Leukemia
University Hospital, Caen100 enrolled1 locationNCT06045819
Recruiting
Not Applicable
Value of Biological Age, in Addition to Individual Frailty, for Personalising the Management of Cancer Treated with Targeted Therapy
Leukemia,Myeloid, Chronic
University Hospital, Clermont-Ferrand321 enrolled17 locationsNCT06130787
Recruiting
Phase 2Phase 3
Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR
Acute Myeloid Leukemia (AML)
University Hospital, Angers3,100 enrolled56 locationsNCT02416388
Recruiting
Incidence of Neutropenic Enterocolitis Study in Acute Myeloid Leukemia Patients During Intensive Therapy
Acute Myeloid Leukemia
Centre Hospitalier Universitaire, Amiens170 enrolled3 locationsNCT03450512
Recruiting
Acute Myeloid Leukemia At Initial Diagnosis and/or Relapse in Children, Teenagers and Young Adults: Molecular Profiling, Multidrug Testing and MSC Interaction Studies
Acute Myeloid LeukemiaGenetic Predisposition to Disease
Assistance Publique - Hôpitaux de Paris500 enrolled28 locationsNCT05772559
Recruiting
Phase 1Phase 2
Sulfasalazine in AML Treated by Intensive Chemotherapy: Elderly Patients-first Line Treatment
Acute Myeloid Leukemia
Assistance Publique - Hôpitaux de Paris64 enrolled13 locationsNCT05580861
Recruiting
Chronic Myeloid Leukemia (CML) Real-Life Database
Chronic Myeloid Leukemia (CML)
University Hospital, Clermont-Ferrand3,500 enrolled14 locationsNCT05963061
Recruiting
Not Applicable
EPIgenetics and in Vivo Resistance of Chronic Myeloid Leukemia Stem Cells to Tyrosine Kinase Inhibitors
Chronic Myeloid Leukemia (CML)Chronic Phase
University Hospital, Clermont-Ferrand160 enrolled16 locationsNCT03481868
Recruiting
Phase 2
CPX-351 vs Intensive Chemotherapy in Patients With de Novo Intermediate or Adverse Risk AML Stratified by Genomics
Acute Myeloid Leukemia
Centre Hospitalier Universitaire de Nice210 enrolled30 locationsNCT05260528